| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2022: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2021: ¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2020: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Outline of Final Research Achievements |
Research was conducted to gain a comprehensive understanding of the function of Reelin and its molecular mechanisms in the expression of higher-order functions in the adult brain, and to develop novel therapies for psychiatric disorders. We found that the C-terminal region of Reelin enhances signaling through a novel receptor, that the Reelin-degrading enzyme ADAMTS-3 regulates oligodendrocyte migration, that ADAMTS-3 inhibition in the postnatal brain ameliorates Alzheimer's disease, and that administration of Reelin to the postnatal cerebellum partially restores behavioral abnormalities.
|
